Oslo  (Norway), 20 February 2019 - Exercise of employee share options, mandatory
notification  of  trade  and  resolution  to  increase  the share capital in PCI
Biotech Holding ASA (the "Company").

1.   Options exercised and mandatory notification of trade on 20 February 2019
Participants  in the  Company's share  option program  have on 20 February 2019
exercised  a total  number of  61,000 share options.  Out of these share options
30,000 were  exercised at a strike price of NOK 19.24, 15,000 share options were
exercised  at a strike price of NOK 7.84, 11,000 share options were exercised at
a  strike price of NOK  3.26 and 5,000 share options were  exercised at a strike
price of NOK 21.48.

Out  of the total  number of exercised  share options, 5,000 share  options at a
strike price of NOK 21.48 and 6,000 share options at a strike price of NOK 3.26
are  exercised by the primary insider Gaël L'Hévéder (CBDO), who has sold 5,300
shares  in the  market at  an average  price of  NOK 25.75 per share in order to
finance  the  cash  and  tax  impact  of  the  share  option exercise. After the
transaction  Mr. L'Hévéder  hold 67,700 shares  and 10,000 share  options in the
Company.

Out  of the total number  of exercised share options,  30,000 share options at a
strike  price of NOK 19.24 are exercised  by the primary insider Hans Olivecrona
(CMO),  who has  sold all  30,000 shares in  the market  at an  average price of
NOK 25.75  per share.  After the  transaction Mr.  Olivecrona hold  0 shares and
60,000 share options in the Company.

This  announcement also represents  a mandatory notification  of trade, which is
submitted by the Company on behalf of the primary insiders.

2.   Resolution to increase the share capital
Following the exercise of share options on 20 February 2019, the Company's Board
of  Directors,  pursuant  to  an  authorisation  granted by the Company's Annual
General  Meeting on  29 May 2018, has  decided to  increase the  Company's share
capital  with NOK 183,000 by issuing 61,000 new  shares, each share of par value
NOK 3.00. Subsequent to the transaction, the Company's share capital will be NOK
111,677,670 divided  into 37,225,890 shares,  each with  a nominal  value of NOK
3.00 and  each giving  one vote  at the  Company's general  meeting. The capital
increase will result in gross proceeds of NOK 838 060.

Contact information:
Ronny Skuggedal, CFO
rs@pcibiotech.no
Mobile: +47 9400 5757

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.